Norland to launch physician bone densitometer:
This article was originally published in Clinica
Executive Summary
US sales of Norland Medical Systems' OsteoAnalyser SXA3000 bone densitometer are due to begin in October. Designed for measuring bone mineral density in the primary care practitioner's office, the system is priced at $19,900. The company has sold over 750 pDEXA desktop densitometers since US introduction last year (see Clinica No 676, p 18). Norland has withdrawn its planned stock offering in view of the general stock market decline and the fall in its share price, which closed at $16 on August 6th.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.